IT life sciences leader | ex-BCG

Date of management change: February 25, 2025 

What Happened?

 

About the Company

Syndax is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple-negative breast cancer (TNBC). Entinostat is an oral, small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body`s immune response to tumors. Entinostat is being evaluated as a combination therapeutic in Phase 1b/2 clinical trials with Merck and Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Merck KGaA, Darmstadt, Germany and Pfizer Inc. in ovarian cancer. Syndax is also developing entinostat as a combination therapeutic in a Phase 3 clinical trial that is being conducted with ECOG-ACRIN for advanced hormone receptor positive breast cancer.

 

About the Person

 

Info Source

News

 
 

Other IT executives who recently changed jobs as well: Meyer Lori, Edwards John, Aboujaoude Christian, Viciana Kenneth, Meeks Brandon, Byrkit Craig, Brown Loren, Sanders Ben, Kopelke Sean, Johnson Katherine, Kwarteng Bettina

You can find the full directory of IT executives here.

How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.